Optimal site of care for administration of extended half-life respiratory syncytial virus (RSV) antibodies to infants in the United States (US).

MLA

Nelson, Christopher B., et al. “Optimal Site of Care for Administration of Extended Half-Life Respiratory Syncytial Virus (RSV) Antibodies to Infants in the United States (US).” Vaccine, vol. 41, no. 40, Sept. 2023, pp. 5820–24. EBSCOhost, https://doi.org/10.1016/j.vaccine.2023.06.089.

APA

Nelson, C. B., Brady, B. L., Richards, M., Lew, C. R., Via, W. L., Greenberg, M., & Rizzo, C. (2023). Optimal site of care for administration of extended half-life respiratory syncytial virus (RSV) antibodies to infants in the United States (US). Vaccine, 41(40), 5820–5824. https://doi.org/10.1016/j.vaccine.2023.06.089

Chicago

Nelson, Christopher B., Brenna L. Brady, Megan Richards, Carolyn R. Lew, William La Via, Michael Greenberg, and Christopher Rizzo. 2023. “Optimal Site of Care for Administration of Extended Half-Life Respiratory Syncytial Virus (RSV) Antibodies to Infants in the United States (US).” Vaccine 41 (40): 5820–24. doi:10.1016/j.vaccine.2023.06.089.